ISARIC provides a collaborative platform through which global, patient‐oriented clinical studies can be developed, executed and shared.
Protocols addressing the most important questions between and during epidemics of severe acute respiratory infections and other rapidly emerging public health threats are undertaken in order to generate new knowledge, maximise the availability of clinical information, and thereby save lives.
Healthcare professionals in COVID-19 hospital (Photo credit: Professor Bin Cao, China-Japan Friendship Hospital, China)
International Severe Acute Respiratory and emerging Infection Consortium
LATEST: MONKEYPOX RESPONSE
The ISARIC-WHO Clinical Characterisation Protocol has been activated in the UK and an updated case report form has been shared with ISARIC Partners in other countries for implementation. ISARIC also has an observational cohort study, currently being used in Central African Republic, and now expanding across Europe. Click here for a summary of ISARIC Monkeypox activities.
Researchers have launched a new study to improve our understanding of monkeypox disease. The first patients have now been recruited at Hôpitaux Universitaires de Genève (HUG) in Switzerland. Click here to read more.
What we do
Our purpose is to prevent illness and deaths from infectious disease outbreaks.
We are a global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseases.
In December 2019, a novel coronavirus (SARS-CoV-2) emerged to cause a pandemic of a severe coronavirus disease (COVID-19). ISARIC has created tools for investigators to collect and store data in a standardised way and has supported clinical trials of treatments.
See below our featured research areas:
The Pandemic Sciences Institute hosted the ‘Key Features of Technology Platforms for R&D to Rapidly Respond to New Outbreaks’ Webinar
The Pandemic Sciences Institute hosted the 'Key Features of Technology Platforms for R&D to Rapidly Respond to New Outbreaks' Webinar.
A multi-country study of monkeypox being launched – first cases enrolled in Geneva
Event date - 10/06/2021
Plasma from patients who have recovered from SARS-CoV-2 infection (convalescent plasma) contains antibodies that can bind to and neutralise the virus.
Event date - 17/12/2020
This forum aims to review evidence and strategies for Non-invasive ventilation (NIV) in COVID, develop and promote research ideas and evidence-based practice.
Event date - 09/12/2020
Currently very little is known about the clinical, biological, psychological and socio-environmental impact of Coronavirus Disease 2019 (COVID-19). While most people have uncomplicated recoveries, some continue to live with prolonged illness and symptoms.